Oral Progesterone for Prevention of Preterm Birth

Completed · Phase 3 · Has a placebo group

Conditions studied: Preterm Birth

In brief

To evaluate whether daily oral micronized progesterone is effective in preventing recurrent spontaneous preterm birth (RSPB) and whether micronized progesterone use increases maternal serum progesterone levels.

Key facts

Study ID

NCT01180296

Run by

Fetal Medicine Foundation

People needed

36

Starts

2006-11-01

Expected to finish

2009-01-01

Last updated by the study team

2019-02-18

Who can join

Age: 18 and older, up to 45. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• pregnant women less than 20 weeks' gestation who had at least one prior spontaneous preterm birth of a liveborn baby between 20 \& 0/7 weeks' and 36 \& 6/7 weeks' gestation.

You may not qualify if…

• multiple gestations, the presence of major fetal anomalies, progesterone use in the current pregnancy (ongoing or past), the presence of a cervical cerclage, and the presence of a placenta previa.

Where it is running

• Miami Valley HospitaL — Dayton, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.